3-hydroxybutyric acid has been researched along with Glycosuria in 12 studies
3-Hydroxybutyric Acid: BUTYRIC ACID substituted in the beta or 3 position. It is one of the ketone bodies produced in the liver.
3-hydroxybutyric acid : A straight-chain 3-hydroxy monocarboxylic acid comprising a butyric acid core with a single hydroxy substituent in the 3- position; a ketone body whose levels are raised during ketosis, used as an energy source by the brain during fasting in humans. Also used to synthesise biodegradable plastics.
Glycosuria: The appearance of an abnormally large amount of GLUCOSE in the urine, such as more than 500 mg/day in adults. It can be due to HYPERGLYCEMIA or genetic defects in renal reabsorption (RENAL GLYCOSURIA).
| Excerpt | Relevance | Reference |
|---|---|---|
| " Routine blood examinations, fructosamine, beta-hydroxybutyrate (BHB), nonesterified fatty acids (NEFA), glucagon, adiponectin, and leptin were measured before and after treatment, also water intake, and urinary electrolytes, glucose, and volume." | 3.88 | Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats. ( Clark, M; Hoenig, M; Reiche, D; Schaeffer, DJ, 2018) |
| "Youth with type 1 diabetes (T1D) infrequently achieve HbA1c targets." | 2.84 | Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes. ( Aschemeier, B; Biester, T; Danne, T; Fath, M; Frey, M; Kordonouri, O; Scheerer, MF, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 6 (50.00) | 18.2507 |
| 2000's | 1 (8.33) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Biester, T | 1 |
| Aschemeier, B | 1 |
| Fath, M | 1 |
| Frey, M | 1 |
| Scheerer, MF | 1 |
| Kordonouri, O | 1 |
| Danne, T | 1 |
| Hoenig, M | 1 |
| Clark, M | 1 |
| Schaeffer, DJ | 1 |
| Reiche, D | 1 |
| Ferrannini, E | 1 |
| Baldi, S | 1 |
| Frascerra, S | 1 |
| Astiarraga, B | 1 |
| Heise, T | 1 |
| Bizzotto, R | 1 |
| Mari, A | 1 |
| Pieber, TR | 1 |
| Muscelli, E | 1 |
| Hayashi, T | 1 |
| Ago, K | 1 |
| Ago, M | 1 |
| Ogata, M | 1 |
| Meier, S | 1 |
| Gore, PJ | 1 |
| Barnett, CM | 1 |
| Cursons, RT | 1 |
| Phipps, DE | 1 |
| Watkins, KA | 1 |
| Verkerk, GA | 1 |
| Amaral-Phillips, DM | 1 |
| McGilliard, AD | 1 |
| Lindberg, GL | 1 |
| Veenhuizen, JJ | 1 |
| Young, JW | 1 |
| Jiffri, E | 1 |
| Broom, J | 1 |
| Whiting, PH | 1 |
| Birkhahn, RH | 1 |
| McCombs, C | 1 |
| Clemens, R | 1 |
| Hubbs, J | 1 |
| Overton, TR | 1 |
| Drackley, JK | 1 |
| Ottemann-Abbamonte, CJ | 1 |
| Beaulieu, AD | 1 |
| Clark, JH | 1 |
| Ferré, P | 1 |
| Pénicaud, L | 1 |
| Hitier, Y | 1 |
| Meier, M | 1 |
| Girard, J | 1 |
| Briffeuil, P | 1 |
| Huynh Thu, T | 1 |
| Kolanowski, J | 1 |
| Smalley, DL | 1 |
| Bradley, ME | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of SGLT-2 Inhibitor on Myocardial Perfusion, Function and Metabolism in Type 2 DM Patients at High Cardiovascular Risk: The SIMPle Randomized Clinical Trial[NCT03151343] | Phase 3 | 92 participants (Actual) | Interventional | 2017-03-29 | Completed | ||
| Sodium-Glucose Cotransporter-2 Inhibitors: A Potential Novel Treatment for Epilepsy[NCT05512130] | Early Phase 1 | 18 participants (Anticipated) | Interventional | 2022-08-17 | Recruiting | ||
| Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease[NCT05719714] | Phase 1/Phase 2 | 60 participants (Anticipated) | Interventional | 2023-11-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for 3-hydroxybutyric acid and Glycosuria
10 other studies available for 3-hydroxybutyric acid and Glycosuria
| Article | Year |
|---|---|
Effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor velagliflozin, a new drug with therapeutic potential to treat diabetes in cats.
Topics: 3-Hydroxybutyric Acid; Adiponectin; Animals; Cat Diseases; Cats; Diabetes Mellitus; Drinking; Electr | 2018 |
Positional asphyxia or diabetic ketoacidosis? A case report.
Topics: 3-Hydroxybutyric Acid; Acetone; Aged; Asphyxia; Diabetic Ketoacidosis; Diabetic Nephropathies; Femal | 2011 |
Metabolic adaptations associated with irreversible glucose loss are different to those observed during under-nutrition.
Topics: 3-Hydroxybutyric Acid; Adaptation, Physiological; Animals; Cattle; Cattle Diseases; Fatty Acids, Non | 2008 |
Effects of decreased availability of glucose for dairy cows.
Topics: 3-Hydroxybutyric Acid; Animals; Cattle; Diet; Energy Metabolism; Fatty Acids, Nonesterified; Female; | 1993 |
Altered renal intermediary metabolism and the onset of renal dysfunction in the streptozotocin diabetic rat.
Topics: 3-Hydroxybutyric Acid; Animals; Creatinine; Diabetes Mellitus, Experimental; Diabetic Nephropathies; | 1996 |
Potential of the monoglyceride and triglyceride of DL-3-hydroxybutyrate for parenteral nutrition: synthesis and preliminary biological testing in the rat.
Topics: 3-Hydroxybutyric Acid; Animal Nutritional Physiological Phenomena; Animals; Body Weight; Cohort Stud | 1997 |
Metabolic adaptation to experimentally increased glucose demand in ruminants.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Blood Urea Nitrogen; Disease Models, Animal; Fatty Ac | 1998 |
Hypoglycemic effects of a beta-agonist, Ro 16-8714, in streptozotocin-diabetic rats: decreased hepatic glucose production and increased glucose utilization in oxidative muscles.
Topics: 2-Hydroxyphenethylamine; 3-Hydroxybutyric Acid; Adrenergic beta-Agonists; Animals; Diabetes Mellitus | 1992 |
Reappraisal of the role of insulin on sodium handling by the kidney: f1fect of intrarenal insulin infusion in the dog.
Topics: 3-Hydroxybutyric Acid; Animals; Blood Glucose; Blood Pressure; Dogs; Fatty Acids, Nonesterified; Fem | 1992 |
New test for urinary glucose (BM33071) evaluated.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Ascorbic Acid; Evaluation Studies as Topic; Glucosephosphate D | 1985 |